Pacira Biosciences, Inc. current report, 30 June 2016

Full document

Business Context and Reporting Period

This Form 8-K Current Report from Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.) is dated June 30, 2016. The filing addresses the termination of a material definitive agreement with CrossLink BioScience, LLC regarding the promotion and sale of the product EXPAREL.

Key Financial Metrics

The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data for the period. The primary financial disclosure relates to a specific liability:

  • Termination Fee Liability: Approximately $7.3 million.
  • Payment Terms: Payable quarterly over two years, commencing in the fourth quarter of 2016.
  • Accounting Treatment: The liability is recorded as of June 30, 2016. The charge is classified as non-recurring and initially non-cash.

Material Changes

The material change reported is the election to terminate the Master Distributor Agreement with CrossLink BioScience, LLC, effective September 30, 2016. This action triggers the aforementioned termination fee obligation.

Guidance, Outlook, and Risks

Management Commentary and Guidance:

  • The $7.3 million termination fee will be excluded from the Company's previously provided 2016 non-GAAP guidance for selling, general, and administrative (SG&A) expenses.
  • The 2016 non-GAAP SG&A guidance remains between $125 million and $135 million, excluding this specific charge.
Risks and Contingencies:
  • The filing includes a Safe Harbor statement noting that forward-looking statements regarding the termination fee and expense estimates are subject to risks and uncertainties.
  • Actual results may differ materially from estimates due to factors discussed in the Company's 2015 Form 10-K.

Investor Verification Checklist

  • Verify the exact calculation methodology for the $7.3 million termination fee based on earned performance-based fees.
  • Confirm the impact of the termination on future revenue streams from EXPAREL following the September 30, 2016 effective date.
  • Review the Company's cash flow projections to ensure liquidity is sufficient to cover the quarterly payments starting in Q4 2016.
  • Check subsequent filings for any updates to the 2016 non-GAAP SG&A guidance if the exclusion of this fee alters the reported figures.